RIKER LAUREN 4
4 · Pacira BioSciences, Inc. · Filed Jun 13, 2024
Insider Transaction Report
Form 4
RIKER LAUREN
Senior Vice President, Finance
Transactions
- Award
Common Stock
2024-06-12+21,360→ 42,045.335 total - Sale
Common Stock
2024-06-12$28.72/sh−3,970$114,018→ 38,075.335 total
Footnotes (3)
- [F1]Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2025, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.33 to $29.32, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3.